CAR-T cells engineered to target specific GBM antigens, such as epidermal growth factor receptor variant III (EGFRvIII) and interleukin-13 receptor alpha 2 (IL13Rα2), have shown potent anti-tumor activity in vitro and in vivo (Hoogstrate et al., 2022; Bagley et al., 2024a). The gene discussed is IL13RA2; the disease is neoplasm.